Coherent Inc. (COHR) Jumps 23.77% on January 29

Equities Staff |

Coherent Inc. (COHR) was among the biggest gainers on the Russell 2000 for Friday January 29 as the stock popped 23.77% to $77.41, representing a gain of $14.865 per share. Some 997,439 shares traded hands on 9,059 trades, compared with an average daily volume of 144,101 shares out of a total float of 24.19 million. The stock opened at $69.74 and traded with an intraday range of $82.76 to $68.50.

After today's gains, Coherent Inc. reached a market cap of $1.87 billion. Coherent Inc. has had a trading range between $69.67 and $52.15 over the last year, and it had a 50-day SMA of $64.29 and a 200-day SMA of $61.15.

The stock has a P/E Ratio of 20.5.

Coherent Inc is a supplier of photonics-based solutions in a range of commercial and scientific research applications. It designs, manufactures, services and markets lasers and related accessories for a diverse group of customers.

Coherent Inc. is based out of Santa Clara, CA and has some 2,586 employees. Its CEO is John R. Ambroseo.

For a complete fundamental analysis analysis of Coherent Inc., check out’s Stock Valuation Analysis report for COHR. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…